|
02 Jun 2025 |
SBI Life Insurance
|
Consensus Share Price Target
|
1810.40 |
1937.59 |
- |
7.03 |
buy
|
|
|
|
|
19 May 2025
|
SBI Life Insurance
|
Geojit BNP Paribas
|
1810.40
|
2048.00
|
1770.00
(2.28%)
|
13.12 |
Buy
|
|
|
In Q4FY25, SBI Life reported a decline in both net premium and total income. Despite this, the company remains strategically focused on long-term growth through strengthening its agency and bancassurance channels, improving the product mix with increased emphasis on non-ULIP and protection products, advancing digital capabilities, and expanding its presence in underserved regions....
|
|
29 Apr 2025
|
SBI Life Insurance
|
KRChoksey
|
1810.40
|
1955.00
|
1730.10
(4.64%)
|
7.99 |
Accumulate
|
|
|
SBI Life’s GWP for Q4FY25 stood at INR 240,016 Mn., a decline of 4.9% YoY (-4.0% QoQ), led by lower new business premium. The VNB Margin expanded by 213bps YoY (+351 bps QoQ) in Q4FY25 to 30.5%.
|
|
25 Apr 2025
|
SBI Life Insurance
|
Emkay
|
1810.40
|
1950.00
|
1695.10
(6.80%)
|
7.71 |
Buy
|
|
|
SBI Life reported an impressive performance for Q4FY25/FY25 with VNB margin at 30.5%/27.8%, respectively, clocking in 7.2% VNB growth for FY25.
|
|
25 Apr 2025
|
SBI Life Insurance
|
Axis Direct
|
1810.40
|
1900.00
|
1695.10
(6.80%)
|
4.95 |
Buy
|
|
|
We maintain our BUY recommendation on the stock
|
|
25 Apr 2025
|
SBI Life Insurance
|
BOB Capital Markets Ltd.
|
1810.40
|
2008.00
|
1695.10
(6.80%)
|
10.91 |
Buy
|
|
|
Moderate APE growth of 2% YoY in Q4FY25, 9% YoY in FY25; while VNB margins expand ~200bps YoY in Q4
|
|
24 Apr 2025
|
SBI Life Insurance
|
Motilal Oswal
|
1810.40
|
2000.00
|
1608.20
(12.57%)
|
10.47 |
Buy
|
|
|
SBI Life Insurance (SBILIFE) reported 2% YoY growth in new business APE to INR54.5b (in line). For FY25, it grew 8% YoY to INR214.2b. Absolute VNB grew 10% YoY to INR16.6b (14% beat). VNB margin for the quarter stood at 30.5% vs. our estimate of 27.4% (28.3% in 4QFY24).
|
|
17 Feb 2025
|
SBI Life Insurance
|
Axis Direct
|
1810.40
|
1609.00
|
1476.20
(22.64%)
|
Target met |
Buy
|
|
|
We recommend a BUY rating on the stock with a target price of Rs 1,609/ share, implying an upside of 10% from the CMP.
|
|
20 Jan 2025
|
SBI Life Insurance
|
Axis Direct
|
1810.40
|
1850.00
|
1499.70
(20.72%)
|
2.19 |
Buy
|
|
|
We maintain our BUY recommendation on the stock
|
|
20 Jan 2025
|
SBI Life Insurance
|
KRChoksey
|
1810.40
|
1901.00
|
1499.70
(20.72%)
|
5.00 |
Buy
|
|
|
The Gross Written Premium (GWP) for Q3FY25 stood at INR 249,978 Mn, a growth of 11.3% YoY (+22.5% QoQ), primarily led by the renewal premium. GWP was 1.9% lower than our estimates.
|
|
20 Jan 2025
|
SBI Life Insurance
|
BOB Capital Markets Ltd.
|
1810.40
|
1995.00
|
1499.70
(20.72%)
|
10.20 |
Buy
|
|
|
Strong APE growth YoY while margins contract in 9M on shift towards ULIP mix and new surrender guidelines
|
|
19 Jan 2025
|
SBI Life Insurance
|
Emkay
|
1810.40
|
1850.00
|
1540.50
(17.52%)
|
2.19 |
Buy
|
|
|
We upgrade SBI Life to BUY from Add with revised up Dec-25E TP of Rs1,850, implying FY26E P/EV of 2.3x. SBI Life delivered an impressive performance in Q3FY25 with growth rebound in the banca channel (10% YoY in Q3 vs 7% in H1), which led to Retail APE growth of 13% in Q3 on a strong base of last year, and VNB margins for the quarter coming in at 26.95% vs 26.86% of 9M despite implementation of the new surrender regulations.
|
|
18 Jan 2025
|
SBI Life Insurance
|
Motilal Oswal
|
1810.40
|
1900.00
|
1540.50
(17.52%)
|
4.95 |
Buy
|
|
|
SBI Life Insurance (SBILIFE) reported strong performance in 3QFY25. APE grew 13% YoY to INR69.4b (5% beat). For 9MFY25, it grew 11% YoY to INR159.7b
|
|
18 Nov 2024
|
SBI Life Insurance
|
ICICI Direct
|
1810.40
|
1800.00
|
1562.60
(15.86%)
|
Target met |
Buy
|
|
|
|
|
14 Nov 2024
|
SBI Life Insurance
|
Geojit BNP Paribas
|
1810.40
|
1748.00
|
1562.30
(15.88%)
|
Target met |
Buy
|
|
|
|
|
25 Oct 2024
|
SBI Life Insurance
|
KRChoksey
|
1810.40
|
1901.00
|
1616.75
(11.98%)
|
5.00 |
Buy
|
|
|
The Gross Written Premium (GWP) for Q2FY25 stood at INR 204,132 Mn, a growth of 1.2% YoY (+31.1% QoQ), primarily led by a 15.8% YoY growth in the renewal premium. GWP missed our estimates.
|
|
24 Oct 2024
|
SBI Life Insurance
|
Asit C Mehta Investment Interrmediates
|
1810.40
|
2015.00
|
1635.30
(10.71%)
|
11.30 |
Buy
|
|
|
SBI Life Insurance reported premium income lower than our estimates by 6% mainly due to weakness in the group insurance and muted growth in the bancassurance channel. In terms of APE, growth was muted at 3% YoY, lower than our estimates by 4%.
|
|
23 Oct 2024
|
SBI Life Insurance
|
Motilal Oswal
|
1810.40
|
2100.00
|
1716.00
(5.50%)
|
16.00 |
Buy
|
|
|
SBI Life Insurance (SBILIFE) reported a weak performance in 2QFY25. APE grew 3% YoY to INR53.9b (11% miss). For 1HFY25, it grew 9% YoY to INR90.3b.
|
|
31 Jul 2024
|
SBI Life Insurance
|
KRChoksey
|
1810.40
|
1985.00
|
1721.05
(5.19%)
|
9.64 |
Buy
|
|
|
The Gross Written Premium (GWP) for Q1FY25 stood at INR 155,721 Mn, a growth of 14.9% (-38.3% QoQ), primarily led by a 16.2% YoY growth in the renewal premium. GWP was in line with our estimates.
|
|
29 Jul 2024
|
SBI Life Insurance
|
Axis Direct
|
1810.40
|
1955.00
|
1746.70
(3.65%)
|
7.99 |
Buy
|
|
|
We maintain our BUY recommendation on the stock.
|
|
25 Jul 2024
|
SBI Life Insurance
|
ICICI Securities Limited
|
1810.40
|
1978.00
|
1695.40
(6.78%)
|
9.26 |
Buy
|
|
|
We remain constructive on SBI Life Insurance (SBLI) basis strength in its distribution and cost structure. While these business moats remain extremely relevant, the wide customer base also makes SBLI least vulnerable to regulatory changes.
|